Biotech · Private company
RECORDATI GROUP
Track this companyFree. Adds RECORDATI GROUP to your Dealase workspace and tells you when its record changes.
Clinical trials2013 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline15
- SiltuximabPhase 3 · Acute Respiratory Distress SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- LCI699Phase 2 · Cushing SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- osilodrostatPhase 2 · Cushing's SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Pasireotide DiaspartatePhase 2 · Post-Bariatric HypoglycemiaClinicalTrials.gov · fetched Nov 12, 2026
- SiltuximabPhase 2 · Idiopathic Multicentric Castleman's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- UdonitrectagPhase 2 · Neurotrophic KeratitisClinicalTrials.gov · fetched Nov 12, 2026
- VehiclePhase 2 · Neurotrophic KeratitisClinicalTrials.gov · fetched Nov 12, 2026
- CabergolineCushing's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Carglumic AcidHyperammonemiaClinicalTrials.gov · fetched Nov 12, 2026
- OsilodrostatHypertensionClinicalTrials.gov · fetched Nov 12, 2026
- OsilodrostatEndogenous Cushing's SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- PasireotideCushing's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- PasireotideCushings DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Pasireotide LARCushing's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SutimlimabCold Agglutinin Disease (CAD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials20
- Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's SyndromePHASE4 · RECRUITING · started Aug 26, 2026ClinicalTrials.gov NCT07247162 · fetched Nov 12, 2026
- Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)PHASE2 · RECRUITING · started Jan 14, 2026ClinicalTrials.gov NCT07104812 · fetched Nov 12, 2026
- Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to EpcoritamabPHASE1 · RECRUITING · started Jan 14, 2025ClinicalTrials.gov NCT06447376 · fetched Nov 12, 2026
- Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal IncidentalomaRECRUITING · started Nov 20, 2024ClinicalTrials.gov NCT06344143 · fetched Nov 12, 2026
- A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell TransplantPHASE2 · RECRUITING · started Nov 6, 2024ClinicalTrials.gov NCT06679829 · fetched Nov 12, 2026
- A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid ReplacementRECRUITING · started Jul 19, 2024ClinicalTrials.gov NCT06430528 · fetched Nov 12, 2026
- A Study of Pasireotide in People With ProlactinomaPHASE2 · RECRUITING · started Feb 27, 2024ClinicalTrials.gov NCT06295952 · fetched Nov 12, 2026
- Pasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 4, 2024ClinicalTrials.gov NCT05928390 · fetched Nov 12, 2026
- Screening Trial for Pain Relief in Schwannomatosis (STARFISH)PHASE2 · RECRUITING · started Aug 31, 2023ClinicalTrials.gov NCT05684692 · fetched Nov 12, 2026
- An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and PediatricsRECRUITING · started Jun 30, 2022ClinicalTrials.gov NCT05040178 · fetched Nov 12, 2026
- Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's SyndromeACTIVE_NOT_RECRUITING · started Jun 13, 2022ClinicalTrials.gov NCT05382156 · fetched Nov 12, 2026
- Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's SyndromePHASE2 · RECRUITING · started Apr 28, 2021ClinicalTrials.gov NCT03708900 · fetched Nov 12, 2026
- Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman DiseasePHASE2 · TERMINATED · started Mar 31, 2021ClinicalTrials.gov NCT04838860 · fetched Nov 12, 2026
- SILtuximab in Viral ARds (SILVAR) StudyPHASE3 · TERMINATED · started Nov 13, 2020ClinicalTrials.gov NCT04616586 · fetched Nov 12, 2026
- REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult PatientsPHASE2 · COMPLETED · started Oct 13, 2020ClinicalTrials.gov NCT04276558 · fetched Nov 12, 2026
- Cold Agglutinin Disease Real World Evidence RegistryACTIVE_NOT_RECRUITING · started Dec 12, 2019ClinicalTrials.gov NCT05791708 · fetched Nov 12, 2026
- Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699PHASE2 · COMPLETED · started Oct 5, 2018ClinicalTrials.gov NCT03606408 · fetched Nov 12, 2026
- Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesPHASE4 · COMPLETED · started Jun 10, 2013ClinicalTrials.gov NCT01794793 · fetched Nov 12, 2026
- Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's DiseaseCOMPLETED · started Mar 28, 2013ClinicalTrials.gov NCT02310269 · fetched Nov 12, 2026
- Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)PHASE2 · COMPLETED · started Feb 1, 2011ClinicalTrials.gov NCT01253161 · fetched Nov 12, 2026